AI assistant
Q32 Bio Inc. — Director's Dealing 2024
Aug 14, 2024
34891_dirs_2024-08-14_97a032ee-4f6a-422d-ad5b-1aead0e10136.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Q32 Bio Inc. (QTTB)
CIK: 0001661998
Period of Report: 2024-04-01
Reporting Person: GRAYZEL DAVID S. (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-04-01 | Stock Option (Right to Buy) | $18.00 | A | 2569 | Acquired | 2034-03-31 | Common Stock (2569) | Direct |
Footnotes
F1: This option was granted in accordance with the Issuer's Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive equity in lieu of cash compensation for services as a non-employee director of the Issuer.
F2: The shares underlying this option shall vest in three equal quarterly installments on each of June 30, 2024, September 30, 2024 and December 31, 2024.
F3: This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.